Bear, H.D., Anderson, S., Brown, A., et al. (2003) The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. Journal of Clinical Oncology, 21, 4165-4174.
https://doi.org/10.1200/JCO.2003.12.005

has been cited by the following article:

• TITLE: The Effect of Neoadjuvant Chemotherapy on ER, PR and HER-2 Expression in Breast Cancer

  AUTHORS: Zheng Nie

  KEYWORDS: Breastcancer, Neoadjuvant Chemotherapy, ER, PR, HER-2

  JOURNAL NAME: Yangtze Medicine, Vol.3 No.3, June 28, 2019

  ABSTRACT: Objective: Through comparativing the change of the ER, PR and HER-2 expression in tumor tissue before and after neoadjuvant chemotherapy (NAC) in locally advanced breast cancer patient, to discuss whether there is influence for NACon ER, PR, HER-2 expression for breast cancer. Also, the relationship of ER, PR, HER-2 and chemosensitivity is also discussed. Methods: The expressions of ER, PR and HER2 in paraffin sections of breast cancer tissues from 51 patients before and after NAC were detected by immunohistochemical method. The assessment for the relationships between ER, PR, HER-2 and the efficiently of NAC is done. Results: For the 51 peoples, there is no statistical significance for change of ER, PR and HER-2 expression before and after NAC (P > 0.05). There is statistical significance for the differences of chemotherapeutic effectiverate between ER negative and ER positive, PR negative and PR positive, HER2 over-expressed group and HER2 non over-expressed group (P Conclusion: NAC maybe could not change the expression of ER and PR, and HER2 for breast cancer patients. The patients with HER-2 over-expressed are not sensitive to chemotherapy, and the patients with ER or PR negative get more benefits from chemotherapy. The breast cancer patients who could obtain pCR could get better prognosis after NAC.